natgillin/translations-raw huggingface dataset:
Asthenia Oedema Pain
Astenija Edem Bol
Asthenia persisted into the follow-up period (median follow-up time of 10 years and 5 months) and was observed to be ongoing in 12 patients (2.3 %) in TAC arm and 4 patients (0.8 %) in FAC arm
Astenija je i dalje bila prisutna u periodu praćenja (medijan vremena praćenja od 10 godina i 5 mjeseci) i zabilježena je u 12 bolesnika (2,3%) u TAC skupini i u 4 bolesnika (0,8%) u FAC skupini.
Asthenia persisted into the follow-up period (median follow-up time of 10 years and 5 months) and was observed to be ongoing in 12 patients (2.3 %) in TAC arm and 4 patients (0.8 %) in FAC arm.
Astenija je i dalje bila prisutna u periodu praćenja (medijan vremena praćenja od 10 godina i 5 mjeseci) i zabilježena je u 12 bolesnika (2,3%) u TAC skupini i u 4 bolesnika (0,8%) u FAC .
Asthenia persisted into the follow-up period (median follow-up time of 10 years and 5 months) and was observed to be ongoing in 12 patients (2.3 %) in TAC arm and 4 patients (0.8 %) in FAC arm.
Astenija je i dalje bila prisutna u periodu praćenja (medijan vremena praćenja od 10 godina i 5 mjeseci) i zabilježena je u 12 bolesnika (2,3%) u TAC skupini i u 4 bolesnika (0,8%) u FAC skupini..
Asthenia persisted into the follow-up period (median follow-up time of 10 years and 5 months) and was observed to be ongoing in 12 patients (2.3%) in TAC arm and 4 patients (0.8%) in FAC arm.
Astenija je i dalje bila prisutna u periodu praćenja (medijan vremena praćenja od 10 godina i 5 mjeseci) i zabilježena je u 12 bolesnika (2,3%) u TAC skupini i u 4 bolesnika (0,8%) u FAC skupini.
Asthenia Pyrexia
astenija pireksija
Asthenia Pyrexia Chills
Bol Astenija Pireksija Zimica
Asthenia*, chills*, fatigue*, malaise*
astenija*, zimica*, umor*, malaksalost
Asthenia*, chills, fatigue*, pyrexia*, influenza-like illness
astenija*, zimica, umor*, pireksija*, bolest nalik gripi
asthenia,
astenija,
asthenia, chest
pireksija*, umor, astenija, bol u
Asthenia, chest pain
astenija, bol u prsima
Asthenia, face oedema, pain, condition aggravated, rigors, tooth disorder
astenija, edem lica, bol, pogoršanje stanja, tresavica, promjene na zubima
Asthenia, face oedema, pain, condition aggravated, rigors, tooth disorder
astenija, edem lica, bol, pogoršanje stanja, tresavica, promjene na zubima,
Asthenia, face oedema, pain, condition aggravated, rigors, tooth disorder
astenija, edem lica, bol, pogoršanje stanja, tresavica, promjene na zubima, promjena osjeta okusa
Asthenia, face oedema, pain, condition aggravated, rigors, tooth disorder
Astenija, edem lica, bol, pogoršanje stanja, tresavica, promjene na zubima.
Asthenia, face oedema, pain, condition aggravated, rigors, tooth disorder
astenija, edem lica, bol, pogoršanje stanja, zimica, promjene na zubima
asthenia, fatigue
astenija, umor
Asthenia, fatigue and malaise
astenija, umor i malaksalost
Asthenia, fatigue, increased fat tissue, malaise
astenija, umor, povećanje masnog tkiva, malaksalost
Asthenia, fatigue, influenza like illness
astenija, umor, simptomi nalik influenci
asthenia, fatigue, malaise, fever
astenija, umor, malaksalost, vrućica
Asthenia, fatigue, mucositis NOS
astenija, umor, nespecificirani mukozitis
Asthenia, fatigue, pain, oedema
astenija, umor, bol, edem
Asthenia, fatigue, pyrexia
astenija, umor, pireksija
asthenia, fever, infusion-associated acute reactions
astenija, vrućica, akutne reakcije povezane s infuzijom
asthenia, fever2, malaise2
astenija, vrućica2, malaksalost2
Asthenia, flushing, hot flushes, condition aggravated, rigors, tongue discolouration, parosmia, thirst
astenija, crvenilo praćeno osjećajem užarenosti, navale vrućine, pogoršanje stanja, tresavica, promjena boje jezika, parosmija, žeđ
Asthenia, flushing, hot flushes, condition aggravated, rigors, tongue discolouration, parosmia, thirst
astenija, crvenilo praćeno osjećajem užarenosti, valunzi vrućine, pogoršanje stanja, zimica, promjena boje jezika, parosmija, žeđ
Asthenia, flushing, hot flushes, condition aggravated, rigors, tongue discolouration, parosmia, thirst
astenija, crvenilo praćeno osjećajem užarenosti, valunzi, pogoršanje stanja, tresavica, promjena boje jezika, parosmija, žeđ
Asthenia, flushing, hot flushes, condition aggravated, rigors, tongue discolouration, parosmia, thirst
astenija, navala crvenila, navale vrućine, pogoršanje stanja, tresavica, promjena boje jezika, parosmija, žeđ
asthenia, irritability
astenija, iritabilnost
Asthenia, Irritability
astenija, razdražljivost
asthenia, malaise
astenija, malaksalost
asthenia, malaise
astenija, slabost
asthenia, malaise
omaglica, pospanost
Asthenia, mucositis NOS
astenija, nespecificirani mukozitis
Asthenia, mucositis NOS
epistaksa
Asthenia, mucous membrane disorder
astenija, poremećaj sluznica
Asthenia, mucous membrane disorder, pain
astenija, poremećaj sluznica, bol
asthenia, oedemau, pyrexia, influenza like illness, chills
astenija, edemu, pireksija, bolest nalik gripi, zimica
asthenia, pain, chest pain, generalised oedema*i, chills
astenija, bol, bol u prsištu, generalizirani edem*i, zimice
Asthenia, peripheral oedema, injection site reactions (including pain, irritation, swelling, induration), chest pain, weight increase, anaphylactic reaction/shock, urticaria
astenija, periferni edemi, reakcije na mjestu injekcije (uključujući bol, nadraženost, oticanje i otvrdnuće), bol u prsima, povećanje tjelesne težine, anafilaktična reakcija/šok, urtikarija
Asthenia, peripheral oedema, injection site reactions (including pain, irritation, swelling, induration), chest pain, weight increase, anaphylactic reaction/shock, urticaria
Astenija, periferni edemi, reakcije na mjestu primjene injekcije (uključujući bol, nadraženost, oteklinu, otvrdnuće), bol u prsištu, povećanje tjelesne težine, anafilaktička reakcija/šok, urtikarija
Asthenia, possibly related to bradycardia
Astenija, moguće povezana s bradikardijom
Asthenia, predominantly mild (CTC grade 1).
Astenija, pretežno blaga (CTC stupanj 1)
asthenia, pyrexia
astenija, pireksija
Asthenia, Pyrexia, Rigors Fatigue**
astenija, pireksija, tresavica, umor
asthenia, thirst
astenija, žeđ
Asthenia.
astenija.
Asthenia/Fatigue
Astenija/umor
Asthenia/fatigue Pain
astenija/umor bol
Asthenia/fatigue, Injection-site haemorrhage, Injection-site induration or warmth, Injection-site mass, Malaise
astenija/umor, krvarenje na mjestu injiciranja, induracija ili toplina na mjestu injiciranja, nakupina tkiva na mjestu injiciranja, malaksalost
asthenia/fatigue, taste perversion, abdominal pain.
astenija/umor, promjena osjeta okusa, bol u abdomenu
asthenia1
astenija1
asthenia1
pankreatitis1
asthenia1, 3
astenija1, 3
Asthenia; injection site reaction; injection site pain; injection site inflammation
astenija; reakcija na mjestu primjene injekcije; bol na mjestu primjene injekcije; upala na mjestu primjene injekcije
Asthenia; non-cardiac chest pain
astenija, bol u prsištu nevezana uz srce
Asthenia; Oedema peripheral; Pyrexia; Fatigue; Mucosal inflammation; Pain; Influenza like illness; Chest pain; Chills
astenija, periferni edem, pireksija, umor, upala sluznice, bol, bolest slična gripi, bol u prsima, zimica
Asthenia; Oedema peripheral; Pyrexia; Fatigue; Mucosal inflammation; Pain; Influenza like illness; Chest pain; Chills
astenija; periferni edem; pireksija; umor; upala sluznice;
Asthenia; Oedema peripheral; Pyrexia; Fatigue; Mucosal inflammation; Pain; Influenza like illness; Chest pain; Chills
astenija; periferni edem; pireksija; umor; upala sluznice; bol; bolest slična gripi; bol u prsima; zimica
Asthenia; Oedema peripheral; Pyrexia; Fatigue; Mucosal inflammation; Pain; Influenza like illness; Chest pain; Chills
astenija; periferni edem; pireksija; umor; upala sluznice; bol; bolest slična gripi; bol u prsnom košu; zimica
Astheniaa
astenijaa
Astheniaa
umora
Astheniaa Fatiguea Mucosal inflammationa Paina
Astenijaa umora upala sluznicea bola
Astheniaa Fatiguea Mucosal inflammationa Paina
Upala sluznicea Bola
asthenia†, peripheral oedema†
astenija†, periferni edem
Asthenic conditions
astenična stanja
asthenopia
astenopija
Asthenopia,
flotirajuće mutnine
asthenopia, blurred vision, conjunctival disorder, conjunctival oedema, iris hyperpigmentation, madarosis, eyelid oedema
astenopija, zamagljen vid, poremećaj konjunktive, edem konjunktive, hiperpigmentacija šarenice, madaroza, edem vjeđe
asthenopia, conjunctival oedema, photophobia, lacrimation increased, iris hyperpigmentation, blurred vision, eyelid pruritus, eyelid oedema
astenopija, konjunktivalni edem, fotofobija, pojačano suzenje, hiperpigmentacija šarenice, zamućen vid, svrbež vjeđe, edem vjeđe
asthenopia, conjunctival oedema, photophobia, tearing, increased iris pigmentation; blurred vision
astenopija, konjunktivalni edem, fotofobija, suzenje, pojačana pigmentacija šarenice; zamućen vid
Asthenopia, Vitreous floaters,
poremećaj šarenice, midrijaza, svjetlosne aureole,
Asthma
+pleuralni izljev
Asthma
astmu
asthma aggravated
pogoršanje astme
Asthma and asthma- related symptoms cases were evaluated in the present PSUR.
Slučajevi astme i simptoma povezanih s astmom ocjenjivani su u sadašnjem PSUR-u.
asthma and related symptoms, pleural effusion and symptoms, respiratory tract congestion and inflammation, cough
astma i s njom povezani simptomi, pleuralni izljev i prateći simptomi, kongestija i upala dišnih puteva, kašalj
Asthma duration, mean in years
Trajanje astme, srednja vrijednost u godinama
Asthma exacerbation
egzacerba cija astme
Asthma exacerbation
egzacerbacija astme
Asthma exacerbations
Egzacerbacije astme
Asthma exacerbations were evaluated only in the exacerbation studies (Studies I and II: reslizumab 3 mg/kg [n=14] and placebo [n=11]).
Egzacerbacija astme bila je procijenjena samo u ispitivanjima egzacerbacije (Ispitivanja I i II: reslizumab u dozi od 3 mg/kg [n=14] i placebo [n=11]).
Asthma is currently a listed ADR in the timolol Product Information.
Astma se trenutno nalazi na popisu nuspojava u informacijama o lijeku za timolol.
asthma medicine, theophylline, salmeterol;
lijekove za astmu teofilin, salmeterol;
asthma medicine, theophylline, salmeterol;
lijekove za astmu, teofilin, salmeterol;
Asthma or history of bronchospasm
Astma ili anamneza bronhospazma
asthma or other breathing problems
astmu ili bilo koji drugi problem s disanjem
asthma, asthma exacerbation, COPD exacerbation and dyspnoea
astma, egzacerbacija astme, egzacerbacija KOBP-a i dispneja
asthma, asthma exacerbation, COPD exacerbation and dyspnoea
astma, egzacerbacija astme, egzacrbacija KOBP-a i dispneja
asthma, asthma exacerbation, COPD exacerbation and dyspnoea
astma,egzacerbacija astme, egzacerbacija KOBP-a i dispneja
asthma, bronchiolitis
astma, obliterirajući bronhiolitis, plućni poremećaj, hipoksija
asthma, bronchiolitis
Manje često
asthma, bronchiolitis obliterans, lung disorder, hypoxia
astma, obliterirajući bronhiolitis, plućni poremećaj, hipoksija
Asthma, Dyspnoea
dispneja pri naporu
asthma, dyspnoea, cough
dispneja,
asthma, dyspnoea.
astma, dispneja
Asthma, Pulmonary congestion, Sinus disorder, Sneezing, Wheezing
astma, plućna kongestija, poremećaj sinusa, kihanje, piskanje pri disanju
Asthma, rhinitis allergic
astma, alergijski rinitis
Asthma, shortness of breath, wheezing
astma, nedostatak zraka, piskanje pri disanju
asthma, too little oxygen reaching the body organs swelling of the stomach.
astma, dotok premale količine kisika u tjelesne organe oticanje trbuha.
Asthma-like symptoms
imptomi slični astmi
Asthma-related adverse events or exacerbations may occur during treatment.
Tijekom liječenja mogu se pojaviti štetni događaji povezani s astmom ili egzacerbacije astme.
Asthma-related death
Smrt povezana s astmom
asthma.
astma.
asthma;
astma,
Astmoor Industrial Estate Runcorn WA7 1NU United Kingdom
Astmoor Industrial Estate Runcorn WA7 1NU Ujedinjeno Kraljevstvo
ASTRAL-1 was a randomised, double-blind, placebo-controlled study that evaluated 12 weeks of treatment with Epclusa compared with 12 weeks of placebo in patients with genotype 1, 2, 4, 5, or 6 HCV infection.
ASTRAL-1 bilo je randomizirano, dvostruko slijepo, placebom kontrolirano ispitivanje za procjenu 12-tjednog liječenja lijekom Epclusa u usporedbi s 12 tjedana primanja placeba u bolesnika zaraženih HCV-om genotipa 1, 2, 4, 5 ili 6.
ASTRAL-2 was a randomised, open-label study that evaluated 12 weeks of treatment with Epclusa compared with 12 weeks of treatment with SOF+RBV in patients with genotype 2 HCV infection.
ASTRAL-2 bilo je randomizirano, otvoreno ispitivanje u kojem se procjenjivalo 12 tjedana liječenja lijekom Epclusa u usporedbi s 12 tjedna liječenja SOF+RBV u bolesnika koji su imali infekciju HCV-om genotipa 2 .
ASTRAL-3 was a randomised, open-label study that evaluated 12 weeks of treatment with Epclusa compared with 24 weeks of treatment with SOF+RBV in patients with genotype 3 HCV infection.
ASTRAL-3 bilo je randomizirano, otvoreno ispitivanje u kojem se procjenjivalo 12 tjedana liječenja lijekom Epclusa u usporedbi s 24 tjedna liječenja sa SOF + RBV u bolesnika koji su imali infekciju HCV-om genotipa 3.
AstraZeneca AB Gärtunavägen, B674:5 SE-151 85 Södertälje Sweden
AstraZeneca AB Gärtunavägen, B674:5 SE-151 85 Södertälje Švedska
AstraZeneca UK Limited Silk Road Business Park
AstraZeneca UK Limited Silk Road Business Park,
AstraZeneca UK Limited Silk Road Business Park Macclesfield
AstraZeneca UK Limited Silk Road Business Park, Macclesfield
AstraZeneca UK Limited, Macclesfield, Cheshire, SK10 2NA, United Kingdom
AstraZeneca UK Limited, Macclesfield, Cheshire, SK10 2NA, Velika Britanija
asymptomatic
porast razina
asymptomatic
razina
Asymptomatic and mild elevations of serum bilirubin have been observed in CAPS patients treated with Ilaris without concomitant elevations of transaminases.
Asimptomatska i blaga povišenja serumskog bilirubina zabilježena su kod bolesnika s CAPS-om liječenih Ilarisom bez istodobnih povišenja transaminaza.
Asymptomatic cases of bradycardia (heart rate less than 60 bpm) have been observed in 10 out of 525 (1.9%) patients treated with ceritinib in clinical studies.
Asimptomatski slučajevi bradikardije (srčane frekvencije niže od 60 otkucaja u minuti) uočeni su u 10 od 525 (1,9%) bolesnika liječenih ceritinibom u kliničkim ispitivanjima.
Asymptomatic creatine phosphokinase (CPK) elevations mainly in association with exercise have also been reported with dolutegravir therapy.
Tijekom terapije dolutegravirom prijavljena su i asimptomatska povećanja razine kreatin fosfokinaze, koja su se uglavnom povezivala s tjelovježbom.
Asymptomatic HIV infection is not expected to affect the safety or efficacy of RotaTeq.
Ne očekuje se da bi asimptomatska infekcija HIV-om mogla utjecati na sigurnost i djelotvornost cjepiva RotaTeq.
asymptomatic hyperlactatemia (build up of acid in your blood)
asimptomatska hiperlaktatemija (nakupljanje kiseline u krvi)
asymptomatic hyperlactatemia (build up of acid in your blood)
asimptomatska hiperlaktatemija (nakupljanjekiseline u krvi)
Asymptomatic increases in blood CPK levels were observed with a higher frequency in the Cotellic plus vemurafenib arm vs placebo plus vemurafenib arm in Study GO28141 (see section 4.2).
U ispitivanju GO28141A, asimptomatska povišenja vrijednosti CPK-a u krvi primijećena su s većom učestalošću u skupini liječenoj lijekom Cotellic plus vemurafenibom nego u onoj koja je primala placebo plus vemurafenib (vidjeti dio 4.2).
Asymptomatic laboratory elevations in blood creatinine
Asimptomatsko povišenje laboratorijskih vrijednosti kreatinina u krvi
At 1 and 24 hours, blood radioactivity decreases from 11.0 % to 0.14 % of the administered activity.
Nakon 1 i 24 sata, radioaktivnost krvi smanjuje se s 11,0% na 0,14% primijenjene aktivnosti.
At 1 month following the 2-dose vaccination course, the percentages of subjects with hSBA ≥1:5 in individuals with complement deficiencies and asplenia or splenic dysfunction were 87% and 97% for antigen fHbp, 95% and 100% for antigen NadA, 68% and 86% for antigen PorA P1.4, 73% and 94% for antigen NHBA, respectively, indicating an immune response in these immunocompromised subjects.
Mjesec dana nakon sheme cijepljenja s 2 doze, postotci ispitanika s hSBA ≥1:5 u osoba s nedostatcima komplementa i asplenijom ili poremećajima funkacije slezene bili su 87% odnosno 97% za antigen fHbp, 95% odnosno 100% za antigen NadA, 68% odnosno 86% za antigen PorA P1.4, 73% odnosno 94% za antigen NHBA, što upućuje na imunološki odgovor u tih imunokompromitiranih ispitanika.
At 1 year post last vaccination, the percentages of subjects with hSBA ≥1:8 after the 2-dose series and the single dose were both lower than at 1 month post-vaccination (30% after the 2-dose series, 11%- 20% after the single dose for serogroup A; 61%-81% and 41%-55% for serogroup C; 92%-94% and 90%-91% for serogroup W135; 67%-75% and 57%-65% for serogroup Y).
Nakon 1 godine od zadnjeg cijepljenja, postotci ispitanika sa hSBA ≥1:8 nakon serije s 2 doze i nakon jednostruke doze bili su niži nego 1 mjesec nakon cijepljenja (30% nakon serije s 2 doze, 11%-20% nakon jednostruke doze za serogrupu A; 61%-81% i 41%-55% za serogrupu C; 92%-94% i 90%-91% za serogrupu W135; 67%-75% i 57%-65% za serogrupu Y).
At 1.8 mg liraglutide, the average steady state concentration of liraglutide (AUCτ/24) reached approximately 34 nmol/l.
Uz 1,8 mg liraglutida, prosječna koncentracija liraglutida (AUCt/24) u stanju dinamičke ravnoteže dostigla je otprilike 34 nmol/l.
At 10 years following the initiation of a 0, 1, 6 month schedule of Twinrix Paediatric in children aged 12-15 years, all subjects followed up retained ≥15 mIU/ml anti-HAV antibody and 85% had anti-HBs antibody ≥10 mIU/ml.
U 10 godina nakon uvođenja rasporeda cijepljenja od 0, 1, 6 mjeseci cjepivom Twinrix Paediatric kod djece u dobi od 12 do 15 godina, svi praćeni ispitanici zadržali su anti-HAV protutijela ≥15 mIU/ml, dok ih je 85% zadržalo anti-HBs protutijela ≥10 mIU/ml.
At 10 years following the initiation of a 0, 6 month schedule of Ambirix in children aged 1-15 years, all subjects followed up retained ≥15 mIU/ml anti-HAV antibody.
Deset godina nakon primjene cjepiva Ambirix po rasporedu 0, 6 mjeseci u djece od 1 do 15 godina, svi ispitanici koji su praćeni zadržali su titar ≥15 mIU/ml anti-HAV protutijela.
At 10 years, 79 of 207 patients originally treated with 40 mg Humira every other week were evaluated radiographically.
U 79 od 207 bolesnika koji su uzimali lijek Humira 40 mg svaki drugi tjedan učinjena je radiografska kontrola nakon 10 godina.
At 102 weeks there were 80 subjects still on infliximab treatment and among those, 71 (89%) were ASAS 20 responders.
102. tjednu infliksimab je i dalje primalo 80 ispitanika, od kojih je 71 (89%) imalo klinički odgovor ASAS 20.
At 102 weeks there were 80 subjects still on infliximab treatment and among those, 71 (89%) were ASAS 20 responders.
102. tjednu infliksimab je i dalje primalo 80 ispitanika, od kojih je 71 (89%) imalo klinički odgovor ASAS- 20.
At 102 weeks, the difference for dapagliflozin as add-on to metformin compared with placebo, or as add-on to insulin compared with placebo was -2.14 and -2.88 kg, respectively.
U 102. tjednu, razlika za dapagliflozin kao dodatak sitagliptinu (sa ili bez metformina) u usporedbi s placebom je bila -2,14 kg, dok je razlika za dapagliflozin kao dodatak inzulinu u usporedbi s placebom bila -2,88 kg.
At 12 hours,
Nakon 12 sati
At 12 months
Nakon 12 mjeseci
At 12 months
U 12. mjesecu
At 12 months median relative changes from baseline were –58.6 % for the intravenous injection of 3 mg every 3 months regimen and –62.6 % for oral 2.5 mg daily regimen.
Nakon 12. mjeseca medijan relativne vrijednosti promjena u odnosu na početne vrijednosti iznosio je -58,6% za liječenje intravenskom injekcijom od 3 mg svaka tri mjeseca i -62,6% za peroralno liječenje dozom od 2,5 mg jedanput dnevno.
At 12 months median relative changes from baseline were –58.6 % for the intravenous injection of 3 mg every 3 months regimen and –62.6 % for oral 2.5 mg daily regimen.
Nakon 12. mjeseca medijan relativne vrijednosti promjena u odnosu na početne vrijednosti iznosio je -58,6% za liječenje intravenskom injekcijom od 3mg svaka tri mjeseca i -62,6% za peroralno liječenje dozom od 2,5mg jedanput dnevno.
At 12 months, the Kaplan–Meier estimates of the likelihood of reaching the endpoint were 10 % in the nevirapine group, 6 % in the efavirenz group, and 13 percent in the abacavir group (P=0.10 according to an intention-to-treat analysis).
Vjerojatnost postizanja primarnog ishoda nakon 12 mjeseci liječenja, procjena po Kaplan-Meieru, bila je 10% za nevirapin, 6% za efavirenz i 13% za abakavir (p=0,10 prema ITT analizi).
At 12 months, the Kaplan–Meier estimates of the likelihood of reaching the endpoint were 10 % in the Viramune group, 6 % in the efavirenz group, and 13 percent in the abacavir group (P=0.10 according to an intention-to-treat analysis).
Vjerojatnost postizanja primarnog ishoda nakon 12 mjeseci liječenja, procjena po Kaplan-Meieru, bila je 10% za Viramune, 6% za efavirenz i 13% za abakavir (p=0,10 prema ITT analizi).
At 12 months, the proportion of patients alive and progression-free was 192 (83%) for patients randomized to vandetanib and 63 (63%) for patients randomized to placebo.
Nakon 12 mjeseci je udio bolesnika koji su bili živi i bez progresije bolesti bio 192 (83%) među bolesnicima randomiziranim na vandetanib i 63 (63%) među bolesnicima randomiziranim na placebo.
At 12 monthsb Cumulative MMRb
U 12. mjesecub Kumulativni MMRb
At 12 monthsc Cumulative CCyRb
U 12. mjesecuc Kumulativni CCyRb
At 12 weeks (primary endpoint), Enurev Breezhaler increased trough FEV1 by 72 ml in patients with the lowest degree of reversibility (<5%) and by 113 ml in those patients with a higher degree of reversibility at baseline (≥5%) compared to placebo (both p<0.05).
12 tjedana (primarna mjera ishoda), Enurev Breezhaler povećao je najniži FEV1 za 72 ml u bolesnika s najnižim stupnjem reverzibilnosti (<5%) te za 113 ml u onih bolesnika koji su imali viši stupanj reverzibilnosti na početku (≥5%) u usporedbi s placebom (oba p<0,05).
At 12 weeks (primary endpoint), Seebri Breezhaler increased trough FEV1 by 72 ml in patients with the lowest degree of reversibility (<5%) and by 113 ml in those patients with a higher degree of reversibility at baseline (≥5%) compared to placebo (both p<0.05).
12 tjedana (primarna mjera ishoda), Seebri Breezhaler povećao je najniži FEV1 za 72 ml u bolesnika s najnižim stupnjem reverzibilnosti (<5%) te za 113 ml u onih bolesnika koji su imali viši stupanj reverzibilnosti na početku (≥5%) u usporedbi s placebom (oba p<0,05).
At 12 weeks (primary endpoint), Tovanor Breezhaler increased trough FEV1 by 72 ml in patients with the lowest degree of reversibility (<5%) and by 113 ml in those patients with a higher degree of reversibility at baseline (≥5%) compared to placebo (both p<0.05).
12 tjedana (primarna mjera ishoda), Tovanor Breezhaler povećao je najniži FEV1 za 72 ml u bolesnika s najnižim stupnjem reverzibilnosti (<5%) te za 113 ml u onih bolesnika koji su imali viši stupanj reverzibilnosti na početku (≥5%) u usporedbi s placebom (oba p<0,05).
At 12, 24 and 36 months, graft and patient survival were similar for both groups.
U obje skupine, preživljenje presatka i bolesnika bilo je slično nakon 12, 24 i 36 mjeseci.
At 14 days after initiation of treatment, 16.7 - 25.0% morbidity and 0.3 - 3.9% mortality were observed in the treated group in comparison to 50.0 - 53.3% morbidity and 0.3 - 4.5% mortality in an untreated group.
Četrnaest dana nakon početka liječenja zabilježena je morbidnost od 16,7-25,0 % i smrtnost od 0,3-3,9 % u liječenoj skupini u usporedbi s morbidnošću od 50,0-53,3 % i smrtnošću od 0,3-4,5 % u neliječenoj skupini.
At 144 weeks in the open- label phase of SINGLE, virologic suppression was maintained, the dolutegravir + ABC/3TC arm (71%) was superior to the EFV/TDF/FTC arm (63%), treatment difference was 8.3% (2.0, 14.6).
U 144. tjednu otvorene faze ispitivanja SINGLE, virološka supresija bila je održana, dolutegravir + ABC/3TC skupina (71%) bila je superiorna u odnosu na EFV/TDF/FTC skupinu (63%), razlika između liječenja bila je 8,3% (2,0; 14,6).